Clinical trial

The Effects of Aripiprazole on Patients With Metabolic Syndrome

NCT00224822

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Aripiprazole Normalized identity: aripiprazoleView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

The Effects of Aripiprazole on Patients With Metabolic Syndrome

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-03-01

PhasePHASE4

Conditions

Schizophreniaverified · MONDO: schizophrenia

Schizoaffective Disorderverified · MONDO: schizoaffective disorder

Bipolar Disorderverified · MONDO: bipolar disorder

Metabolic Syndrome Xverified · MONDO: metabolic syndrome X

Interventions

AripiprazoleDRUG · verified · RxNorm: aripiprazole

Sponsors & collaborators

New Mexico VA Healthcare Systemlead sponsor

Bristol-Myers Squibbcollaborator

Mapped research locations

AlbuquerqueNew Mexico, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00224822 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.